Access Dermatology

Breaking News

• Home »
• Breaking News »
• Breaking News article

Efficacy and safety of pimecrolimus cream in mild-moderate chronic hand dermatitis

A multicenter, randomized, double-blind, vehicle-controlled study of pimecrolimus cream 1% or vehicle was conducted in 652 patients with mild-moderate chronic hand dermatitis. The pimecrolimus or vehicle was applied b.i.d. with occlusion for 6 weeks, followed by a 6-week open-label treatment with pimecrolimus. The primary endpoint was treatment success on the Investigators Global Assessment (IGA), defined by a score of 0 or 1 on the target hand. The treatment success rate after 6 weeks was 29.8 and 23.25% in the pimecrolimus and vehicle groups, respectively (P = 0.057). However, the proportion experiencing pruritus relief at all time points in the double-blind phase was significantly higher in the pimecrolimus group (83.7%) versus the vehicle ...